Intranasal fentanyl for breakthrough pain control

Clinical Medicine Insights: Therapeutics

Volumn 4, Issue , 2012, Pages 241-250

  Clavijo, Claudia F ^a   Lynn, Rachael Rzasa ^a   Christians, Uwe ^a   Galinkin, Jeffrey L ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Breakthrough pain; Cancer pain; Fentanyl; Fentanyl formulations; Intranasal; Rapid onset opioids

Indexed keywords

AMIODARONE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DEXAMETHASONE; DILTIAZEM; EFAVIRENZ; ERYTHROMYCIN; FENTANYL; FENTANYL CITRATE; FLUCONAZOLE; FLUVOXAMINE; HYDROCORTISONE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MORPHINE; NEFAZODONE; NELFINAVIR; NEVIRAPINE; NORFLOXACIN; OPIATE; OXYCODONE; PHENOBARBITAL; PREDNISOLONE; RITONAVIR; SAQUINAVIR; SECOBARBITAL; UNINDEXED DRUG; VERAPAMIL;

BILIARY SMOOTH MUSCLE SPASM; BILIARY TRACT DISEASE; BRADYCARDIA; BREAKTHROUGH PAIN; CANCER PAIN; CHEST WALL RIGIDITY; CHRONIC PAIN; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DRUG USE; ECONOMIC ASPECT; EMOTION; EPISTAXIS; HUMAN; IMMUNE DEFICIENCY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PAIN; PHYSICAL TOLERANCE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH EMPTYING; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE RETENTION; VOMITING;

EID: 84866120362     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S7298     Document Type: Review

References (55)

1. Mishra S, Bhatnagar S, Chaudhary P, Rana SP. Breakthrough cancer pain: review of prevalence, characteristics and management. Indian J Palliat Care. Jan 2009;15(1):14-8.
2. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. Jan 22, 2012;72(2):181-90.
3. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebocontrolled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain. Dec 2010; 151(3):617-24.
4. Mystakidou K, Panagiotou I, Gouliamos A. Fentanyl nasal spray for the treatment of cancer pain. Expert Opin Pharmacother. Jul 2011;12(10):1653-9.
5. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology. Mar 1985;62(3):234-41.
6. Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low-and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. Apr 2003;98(4):853-61.
7. Prommer E, Thompson L. Intranasal fentanyl for pain control: current status with a focus on patient considerations. Patient Prefer Adherence. 2011;5: 157-64.
8. Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. Aug 2011;11(8):1197-216.
9. Kehlet H, Rung GW, Callesen T. Postoperative opioid analgesia: time for a reconsideration? J Clin Anesth. Sep 1996;8(6):441-5.
10. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol. Apr 2001;96(4):1266-72.
11. Streisand JB, Bailey PL, LeMaire L, et al. Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations. Anesthesiology. Apr 1993;78(4):629-34.
12. Fahnenstich H, Steffan J, Kau N, Bartmann P. Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. Crit Care Med. Mar 2000;28(3):836-9.
13. Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology. Feb 1982;56(2): 93-6.
14. Hansen MS, Mathiesen O, Trautner S, Dahl JB. Intranasal fentanyl in the treatment of acute pain-a systematic review. Acta Anaesthesiol Scand. Jan 19, 2012.
15. Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag. Jan-Feb 2010;6(1):17-26.
16. Foster D, Upton R, Christrup L, Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. Oct 2008;42(10):1380-7.
17. Nave R, Sides EH, Colberg T, et al. Higher systemic bioavailability and faster absorption of intranasal fentanyl spray (INFS) compared to ACTIQ (OTFC) in healthy subjects. Eur J Pain. 2009;13(S1):S206.
18. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. Feb 2010;48(2):138-45.
19. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics after administration of 100 ag intranasal fentanyl spray (1 dose vs. 2 doses) in non-elderly and elderly healthy subjects. Eur J Pain. 2009;13(S1):S207.
20. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schnmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetolazine. Eur J Pain. 2009;13(S1):S207.
21. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schnmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Eur J Pain. 2009;13(S1):S207a-S207.
22. Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg Med (Fremantle). Sep 2002;14(3):275-80.
23. Cole J, Shepherd M, Young P. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg Med Australas. Oct 2009;21(5):395-400.
24. Crellin D, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 microg/mL) administered intranasally have analgesic efficacy? Emerg Med Australas. Feb 2010;22(1):62-7.
25. Mudd S. Intranasal fentanyl for pain management in children: a systematic review of the literature. J Pediatr Health Care. Sep-Oct 2011;25(5): 316-22.
26. Younge PA, Nichol MF, Kendall JM, Harrington AP. A prospective randomized pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg Med (Fremantle). 1999;11(2):90-4.
27. Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. Mar 2007;49(3): 335-40.
28. Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg Med Australas. Dec 2008;20(6):515-20.
29. Holdgate A, Cao A, Lo KM. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. Acad Emerg Med. Feb 2010;17(2):214-7.
30. Finn M, Harris D. Intranasal fentanyl for analgesia in the paediatric emergency department. Emerg Med J. Apr 2010;27(4):300-1.
31. Kusre SR. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Bet 4: is intranasal fentanyl better than parenteral morphine for managing acute severe pain in children? Emerg Med J. Dec 2011;28(12):1077-8.
32. Seith RW, Theophilos T, Babl FE. Intranasal fentanyl and high-concentration inhaled nitrous oxide for procedural sedation: a prospective observational pilot study of adverse events and depth of sedation. Acad Emerg Med. Jan 2012;19(1):31-6.
33. Borland ML, Bergesio R, Pascoe EM, Turner S, Woodger S. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns. Nov 2005;31(7):831-7.
34. Galinkin JL, Fazi LM, Cuy RM, et al. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology. Dec 2000;93(6):1378-83.
35. Finkel JC, Cohen IT, Hannallah RS, et al. The effect of intranasal fentanyl on the emergence characteristics after sevoflurane anesthesia in children undergoing surgery for bilateral myringotomy tube placement. Anesth Analg. May 2001;92(5):1164-8.
36. Voronov P, Tobin MJ, Billings K, Cote CJ, Iyer A, Suresh S. Postoperative pain relief in infants undergoing myringotomy and tube placement: comparison of a novel regional anesthetic block to intranasal fentanyl-a pilot analysis. Paediatr Anaesth. Dec 2008;18(12):1196-201.
37. Manjushree R, Lahiri A, Ghosh BR, Laha A, Handa K. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can J Anaesth. Feb 2002;49(2):190-3.
38. Chung S, Lim R, Goldman RD. Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography. Pediatr Radiol. Jul 2010;40(7):1236-40.
39. Friedrichsdorf SJ, Finney D, Bergin M, Stevens M, Collins JJ. Breakthrough pain in children with cancer. J Pain Symptom Manage. Aug 2007;34(2): 209-16.
40. Colberg T, Nolte T, Oronska A, Kaczmarek Z, Kaasa S, Kress H. Titration of intranasal fentanyl for breakthrough pain in patients with cancer: evidence for dose proportionality vs. background analgesia. Ann Oncol. 2009; 19(Suppl 8):257-8.
41. Kaasa S, Marchesini C, Kaczmarek Z, Oronska A, Kress H, Nolte T. Tolerability and safety of intranasal fentanyl treatment for breakthrough pain in patients with cancer: four-month follow-up. Ann Oncol. 2009; 19(Suppl 8):257.
42. Nolte T, Marchesini C, Oronska A, Kaczmarek Z, Kaasa S, Kress H. Efficacy of intranasal fentanyl for breakthrough pain in patients with cancer: results of a Phase III trial. Ann Oncol. 2009;19(Suppl 8):254.
43. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. Jun 2009;31(6): 1177-91.
44. Kress HG, Colberg T. Titration of intranasal fentanyl spray (INFS) for breakthrough pain in cancer patiens: evidence for dose proportionality vs. background analgesia. Eur J Pain. 2009;13:S197.
45. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. Nov 2009;25(11):2805-15.
46. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. May 2010;26(5):1037-45.
47. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. Oct 2000;20(4):253-8.
48. Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage. Feb 2011;41(2):358-66.
49. Levin TT, Bakr MH, Nikolova T. Case report: delirium due to a diltiazemfentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry. Nov-Dec 2010;32(6):648 e649-8 e610.
50. Hallberg P, Marten L, Wadelius M. Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol. Jun 2006;62(6):491-2.
51. Rastogi R, Swarm RA, Patel TA. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology. Dec 2011;115(6):1291-8.
52. Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med. May 2010;38(4):477-80.
53. Davis's Drug Guide for Nurses. 12th ed. Philadelphia, PA: FA Davis Company; 2011.
54. Mouly S, Meune C, Bergmann JF. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Med. Mar 2009;35(3):417-29.
55. Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. Apr 2009;35(4): 603-12.